Invest with us
Help us develop and deliver innovative diagnostic solutions enabling more informed clinical decisions for human and animal health
Our strategic vision
Pictor’s goal is for the company’s multiplex platform to play an increasingly important role in achieving these outcomes through the development, manufacture and marketing of novel IVD products that meet the highest regulatory requirements.
An innovative & unique approach
Pictor’s novel multiplex platform improves human and animal health diagnostics. Our transformative technology has the potential to be a game changer in the fight against infectious diseases in these market segments.
Raising the stakes
The Company’s transition from being solely focused on the low-cost human health diagnostic market of India, to both the high value human health market in the US and livestock diagnostic markets within New Zealand and internationally has continued.
Pictor will enter these new markets in 2022 – 2023 with highly differentiated products:
- The PictArray SARS-CoV-2 ELISA uniquely detects SP and NP antibodies thus enabling positive differentiation between those who have antibodies as a result of vaccination and those who have been infected with the virus and have suffered from COVID-19.
- Pictor’s Mycoplasma bovis (M. bovis) multiplex diagnostic with up to five [5] antigens will help accelerate and assist the eradication of this disease from New Zealand.
- The Pictor Johne’s disease/MAP (Mycobacterium avium subspecies paratuberculosis) diagnostic enables earlier detection and management of this productivity impacting disease that is endemic in New Zealand and other livestock-focused markets.
Request our introductory investor deck.
Everything you and your advisors need to know about becoming a part of Pictor's success.
Trusted Brand
Our partners and
long term clients
Pictor has been collaborating with industry leaders from around the globe.
Labtests
Integrity Sciences
Mobility Health
RakoScience
SVS Laboratories
Asia Pacific Healthcare Group